Abstract
Purpose:
In this retrospective investigation, the outcome and toxicity after reirradiation with concurrent cetuximab immunotherapy of recurrent head and neck cancer (HNC) in patients who had contraindications to platinum-based chemotherapy were analyzed.
Materials and Methods:
Ten patients with locally advanced recurrent HNC were retrospectively evaluated. In 9 cases, histology was squamous cell carcinoma, in one case adenoid cystic carcinoma. External beam radiotherapy was part of the initial treatment in all cases. Reirradiation was carried out using step-and-shoot intensity-modulated radiotherapy (IMRT) with a median dose of 50.4 Gy. Cetuximab was applied as loading dose (400 mg/m2) 1 week prior to reirradiation and then weekly concurrently with radiotherapy (250 mg/m2).
Results:
The median overall survival time after initiation of reirradiation was 7 months; the 1-year overall survival (OS) rate was 40%. Local failure was found in 3 patients, resulting in a 1-year local control (LC) rate of 61%. The 1-year locoregional control (LRC) rate was 44%, while the 1-year distant metastasis-free survival (DMFS) was 75%. Acute hematological toxicity was not observed in the group. Severe acute toxicity included one fatal infield arterial bleeding and one flap necrosis. Severe late toxicities were noted in 2 patients: fibrosis of the temporomandibular joint in 1 patient and stenosis of the cervical esophagus in another.
Conclusions:
IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent HNC is feasible with acceptable acute toxicity. Further investigations are necessary to determine the clinical role of this therapy concept.
Zusammenfassung
Ziel:
In dieser Untersuchung analysierten wir Behandlungsergebnis und Toxizität nach kombinierter Re-Bestrahlung mit simultaner Cetuximab-Immuntherapie von rezidivierten HNO-Tumoren bei Patienten mit Kontraindikation gegen platinhaltige Chemotherapie.
Patientengut und Methode:
10 Patienten mit lokal fortgeschrittenen rezidivierten HNO-Tumoren wurden retrospektiv ausgewertet. In 9 Fällen lag histologisch ein Plattenepithelkarzinom, in einem Fall ein adenoidzystisches Karzinom vor. In jedem Fall war eine Strahlentherapie Teil des initialen Behandlungskonzeptes. Die Re-Bestrahlung wurde mittels Step-and-shoot-IMRT mit einer medianen Dosis von 50,4 Gy durchgeführt. Cetuximab wurde als „Loading Dose“ (400 mg/m2) eine Woche vor Re-Bestrahlung und danach wöchentlich simultan zur Bestrahlung (250 mg/m2) verabreicht.
Ergebnisse:
Das mediane Gesamtüberleben nach Re-Bestrahlung war 7 Monate; das 1-Jahres-Gesamtüberleben betrug 40%. Ein Lokalrezidiv trat bei 3 Patienten auf, was zu einer 1-Jahres-Lokalkontrolle von 61% führte. Die 1-Jahres-lokoregionäre Kontrolle betrug 44%. Das 1-Jahres-Metastasen-freie Überleben war 75% (siehe Abbildungen 1–4). Eine akute hämatologische Toxizität wurde in diesem Kollektiv nicht gesehen. Schwere Akuttoxizitäten waren eine fatale arterielle Blutung und eine Flap-Nekrose. Als schwere Spättoxizität trat eine Fibrose der Pterygiodmuskulatur bzw. des Kiefergelenks sowie eine zervikale Ösophagusstenose auf (vgl. Tabellen 2 u. 3).
Schlussfolgerungen:
Bei rezidivierten HNO-Tumoren ist eine IMRT-Re-Bestrahlung mit 50 Gy und simultaner Cetuximab- Immuntherapie mit einer akzeptablen Toxizität durchführbar. Es sind weitere Untersuchungen nötig, um den Stellenwert dieser Therapieform zu überprüfen.
Similar content being viewed by others
References
Bailet JW, Mark RJ, Abemayor E, et al. Nasopharyngeal carcinoma: treatment and results with primary radiation therapy. Laryngoscope 1992;102:965–72.
Balermpas P, Hambek M, Seitz O, et al. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol 2009;185:775–81.
Biagioli MC, Harvey M, Roman E, et al. Intensity-modulated radiotherapywith concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int J Radiat Biol Phys 2007;69:1076–3.
Bölke E, Gerber PA, Lammering G, et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008;184:105–10.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of head and neck. NEJM 2006;354:567–78.
Chen YJ, Kuo JV, Ramsinghani NS, et al. Intensity-modulated radiotherapy for previously irradiated recurrent head-and-neck cancer. Med Dosim 2002;27:171–6.
Chua DT, Sham JS, Leung LH, et al. Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy. Radiother Oncol 2005;77:290–4.
Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Publish Date: August 9, 2006.
De Crevoisier R, Domenge C, Wibault P, et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 2001;91:2071–6.
Farrag A, Voordeckers M, Tournel K, et al. Pattern of failure after helical tomotherapy in head and neck cancer. Strahlenther Onkol 2010;186:511–6.
Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 1992;10:1245–51.
Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110:1–8.
ICRU Report 50. Prescribing, recording, and reporting photon beam therapy. International Commission on Radiation Units and Measurements, Bethesda, Maryland, USA, 1993.
Janot F, De Raucourt M, Castaing E, et al. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: a randomized trial from the GETTEC and GORTEC groups. J Clin Oncol 2006;24:18.
Kramer NM, Horwitz EM, Cheng J, et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 2005;27:406–14.
Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of the radiation therapy oncology group protocol 9911. J Clin Oncol 2007;25:4800–5.
Machtay M, Rosenthal DI, Chalian AA, et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 59:72–7.
Münter MW, Thilmann C, Hof H, et al. Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. Radiother Oncol 2003;66:313–21.
Patel S, Shah J. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 2005;55:242–58.
Perez CA, Devineni VR, Marcial-Vega V, et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992;23:271–80.
Popovitzer A, Gluck I, Chepeha DB, et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys 2009;74:1342–7.
Pryzant RM, Wendt L., Delclos et al. Retreatment of nasopharyngeal carcinoma in 53 patients. Int J Radiat Oncol Biol Phys 1992;22:941–7.
Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-andneck squamous cell carcinoma. Int J Radiat Biol Phys 2006;64:382–91.
Schlegel W, Kneschaurek P. Inverse radiotherapy planning. Strahlenther Onkol 1999;175:197–207.
Segaert S, Chiritescu G, Lemmens L, et al. Skin toxicities of targeted therapies. Eur J Cancer 2009;45:295–308.
Spencer S, Wheeler R, Peters G, et al. Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer. Head Neck 2003;25:118–22.
Spencer SA, Harris J, Wheeler RH, et al. RTOG 96-10Reirradiation with concurrent hydroxyurea and 5-fluouracil in patients with aquamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001;51:1299–304.
Steinmann D, Cerny B, Karstens JH, et al. Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis. Strahlenther Onkol 2009;185:682–8.
Studer G, Graetz KW, Glanzmann C, et al. Outcome in recurrent head and neck cancer treated with salvage-IMRT. Radiation Oncology 2008;3:43.
Sulman EP, Schwartz DL, Le T, et al. IMRT reirradiation of head and neck cancer – disease control and morbidity outcomes. Int J Radiat Biol Phys 2009;73:399–409.
Tribius S, Kronemann S, Kilic Y, et al. Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck. Strahlenther Onkol 2009;185:675–81.
Van Cruijsen H, Giaccone G, Hoelman K. Epidermal growth factor recptor and angiogenesis: Opportunities for combined anticancer strategies. Int J Cancer 2005;117:883–8.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. NEJM 2008;359(11):1116–27.
Wolff HA, Bosch J, Jung K, et al. High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 2010;186:262–8.
Xia P, Fu KK, Wong GW, et al. Comparison of treatment plans involving intensità-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000;48:329–37.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zwicker, F., Roeder, F., Thieke, C. et al. IMRT Reirradiation with Concurrent Cetuximab Immunotherapy in Recurrent Head and Neck Cancer. Strahlenther Onkol 187, 32–38 (2011). https://doi.org/10.1007/s00066-010-2149-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-010-2149-7